Advanced Proteome Therapeutics Corporation Prepares Proprietary Protein Conjugates to Be Tested for Anti-Cancer Activities

VANCOUVER, BRITISH COLUMBIA--(Marketwire - March 14, 2013) - Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSX VENTURE:APC) announced today that it has achieved the preparation of certain novel, proprietary protein conjugates and multimers that the Company has designed for testing as anticancer agents. (A protein conjugate is a protein that is linked to a non-protein. A multimer is a substance in which more than one protein is linked together.) Using APC technologies, the Company has applied synthetic methods that are site-specific and thus permit the production of homogeneous products, which represent the gold standard of purity in the industry.

The technology is based on APC's proprietary platform that can be used to attach known therapeutic entities to specific sites on a designated protein carrier which has an affinity for cancer cells. The attachments are designed to enhance the properties of the protein targeted for cancer cells and endow it with additional therapeutic functions. The basis of APC's technology is the Foundation Trinity: not only targeted therapy and combination therapy, but homogeneous therapy as well. APC is seeking to establish its Foundation Trinity approach and expand the "classical magic bullet" concept of therapy to a robust version of the "multiple warhead concept" in the War on Cancer.

Alexander (Allen) Krantz, President and CEO, stated that "The preparation of such protein conjugates by APC scientists represents an innovation and important milestone for the Company and shows that Company scientists have amassed significant proprietary know how. It places the Company in a strong position to capitalize on its ability to chemically generate protein conjugates, site specifically, that can be targeted for cancer cells." Site specific modification technology is regarded as key to avoiding heterogeneous mixtures that can compromise biological activity, complicate manufacturing and production processes, and give rise to unwanted toxicities.

As the next step in its plan, APC is currently in negotiation with experts in the cancer field, to test the properties of these agents in their respective laboratories against targeted cancer cells.

In another development, Alexander (Allen) Krantz, Ph.D., has been invited to give the Keynote Address at BIT's 6th Annual World Protein and Peptide Conference (PepCon-2013). The Conference, which will be held during March 21-23, 2013 at Suzhou International Expo Centre, China, will cover 66 Sessions in Protein and Peptide Sciences and is expected to attract 1000 participants. In his address, Dr. Krantz will review the status of protein conjugate drugs and cite advanced approaches to their preparation pursued at APC. He will emphasize site specificity considerations and product homogeneity, standards that have been difficult to achieve in the production of such pharmaceuticals by industry.

About APC

APC specializes in the development and patenting of advanced methods and platform technologies designed to deliver drugs to specific cellular targets. The Company's patent-pending technology creates transportation systems for drugs to target cells that need to be destroyed, such as cancer cells. APC uses its proprietary enabling technology for chemical modification of the carrier proteins. These methods allow the drug, in accord with regulatory requirements, to be site-specifically attached to the carrier protein which tracks to cancers cells. APC is focused on developing the first commercial application of cancer cell targeting by a specific protein family that has an affinity for cancer cells. Due to its high affinity for a target receptor on cancer cells, the protein can function as a transport system for drugs linked to its surface, with the prospect of avoiding the debilitating toxic effects that have plagued the use of chemotherapeutic drugs.

By virtue of a similar affinity of the protein family for cells in the process of dying, the foregoing technologies are also applicable to the repair of cells where loss of function is a critical event, such as in eye diseases and myocardial infarction.

ON BEHALF OF THE BOARD

Alexander (Allen) Krantz, President and Chief Executive Officer

The forward-looking statements contained in this news release involve risks and uncertainties, and are subject to change based on various important factors including timely development and acceptance of new products, gaining product approval, successful entry into new markets, changes in financing conditions, and changes in FDA regulations. Forward looking statements include operating risks such as (i) market acceptance of the Company's technology and products, (ii) the Company's ability to obtain and enforce timely patent protection of its technology and products, (iii) the Company's ability to manufacture its products cost effectively and produce favorable research results; (iv) the competitive environment and impact of technological change, and (v) the continued availability of capital to finance the Company's activities. A listing of potential risks can be found in the Company's SEDAR filings.